Harvard Bioscience
HBIO
71 hedge funds and large institutions have $116M invested in Harvard Bioscience in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
58% more capital invested
Capital invested by funds: $73.8M → $116M (+$42.5M)
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
29% more funds holding
Funds holding: 55 → 71 (+16)
0.18% more ownership
Funds ownership: 6.36% → 6.54% (+0.18%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$3.6M |
| 2 |
ARM
Adirondack Research & Management
Guilderland,
New York
|
+$1.49M |
| 3 |
AIP
ARS Investment Partners
New York
|
+$1.2M |
| 4 |
Millennium Management
New York
|
+$915K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$743K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPC
Glacier Peak Capital
Bellevue,
Washington
|
-$4.99M |
| 2 |
RA
Royce & Associates
New York
|
-$907K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$803K |
| 4 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$642K |
| 5 |
First Manhattan
New York
|
-$432K |
HBIO Hedge Fund Activity: Q1 2018 in Review
71 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2018, worth a combined $116M — up 58% from $73.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new HBIO positions and 4 closed out — a net gain of 16 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $3.6M. The largest seller was Glacier Peak Capital, exiting entirely with an estimated $4.99M sold.
- 71 institutional investors held Harvard Bioscience (HBIO) as of Q1 2018, up from 55 in Q4 2017.
- Funds reported $116M of Harvard Bioscience stock for Q1 2018, up 58% quarter-over-quarter.
- 20 funds opened new Harvard Bioscience positions in Q1 2018 and 4 closed out, a net change of +16 holders.
- The largest Harvard Bioscience buyer in Q1 2018 was First Light Asset Management, an estimated $3.6M added.
- The largest Harvard Bioscience seller in Q1 2018 was Glacier Peak Capital, an estimated $4.99M sold.
Based on aggregated 13F filings for Q1 2018.